LBF20208PG01: Difference between revisions
No edit summary |
No edit summary |
||
Line 6: | Line 6: | ||
|LipidBank=XPR1771 | |LipidBank=XPR1771 | ||
|LipidMaps=LMFA03010101 | |LipidMaps=LMFA03010101 | ||
|SysName= | |SysName=9alpha,15S-dihydroxy-11-oxo-prosta-5Z,12E-dien-1-oic acid | ||
|Common Name=&& | |Common Name=&&delta12-Prostaglandin D_2&&9alpha,15S-dihydroxy-11-oxo-prosta-5Z,12E-dien-1-oic acid&& | ||
|Source= | |Source= | ||
|Chemical Synthesis= | |Chemical Synthesis= |
Revision as of 05:24, 20 January 2010
LipidBank Top (トップ) |
Fatty acid (脂肪酸) |
Glycerolipid (グリセロ脂質) |
Sphingolipid (スフィンゴ脂質) |
Journals (雑誌一覧) |
How to edit (ページの書き方) |
IDs and Links | |
---|---|
LipidBank | XPR1771 |
LipidMaps | LMFA03010101 |
CAS | |
KEGG | {{{KEGG}}} |
KNApSAcK | {{{KNApSAcK}}} |
mol | LBF20208PG01 |
δ12-Prostaglandin D2 | |
---|---|
Structural Information | |
9α,15S-dihydroxy-11-oxo-prosta-5Z,12E-dien-1-oic acid | |
| |
Formula | C20H32O5 |
Exact Mass | 352.224974134 |
Average Mass | 352.46508 |
SMILES | C(CC[C@H](O)CC=C([C@H]1CC=CCCCC(O)=O)C(C[C@@H]1O)=O)CC |
Physicochemical Information | |
d12-PGD2 is catalyzed to d12-PGJ2, which has antimitotic and carcinogenic activities. Kato_T et al. Fukushima_M | |
Spectral Information | |
Mass Spectra | |
UV Spectra | |
IR Spectra | |
NMR Spectra | |
Other Spectra | |
Chromatograms |
Reported Metabolites, References | |||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|